Zacks Investment Research downgraded shares of UROPLASTY INC (UPI) from NEUTRAL to UNDERPERFORM on August 06, 2013, with a target price of $2.50.
Uroplasty is a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. The Company's minimally invasive products treat urinary incontinence and overactive bladder symptoms. They believe that the company is uniquely positioned because we offer a broad and diverse set of products to address the various preferences of doctors and patients, as well as the quality of life issues presented by voiding dysfunctions.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on UROPLASTY INC (UPI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment